Search Cancer Clinical Trials
Recruiting
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. - TriPRIL CAR T Cells - Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
- Multiple Myeloma
- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma
- TriPRIL CAR T Cells
- Cyclophosphamide
- Fludarabine
Phase 1
Interventional
Primary Outcome:
- Incidence of adverse events (AEs)
- Incidence of Dose Limiting Toxicity (DLT)
Secondary Outcome:
- Overall Response Rate (ORR)
- Overall Survival (OS)
- Progression Free Survival (PFS)
18
October 5, 2021
- Gender: All
- Minimum age: 18 Years
- Maximum age: N/A
- Healthy volunteers: No
Marcela V. Maus, M.D.,Ph.D.
Massachusetts General Hospital
A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
NCT05020444
Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.